AR122619A1 - COMPOSITIONS AND METHODS RELATED TO COMPLEMENT FACTOR I - Google Patents

COMPOSITIONS AND METHODS RELATED TO COMPLEMENT FACTOR I

Info

Publication number
AR122619A1
AR122619A1 ARP210101618A ARP210101618A AR122619A1 AR 122619 A1 AR122619 A1 AR 122619A1 AR P210101618 A ARP210101618 A AR P210101618A AR P210101618 A ARP210101618 A AR P210101618A AR 122619 A1 AR122619 A1 AR 122619A1
Authority
AR
Argentina
Prior art keywords
cfi
variants
fusion constructs
complement factor
compositions
Prior art date
Application number
ARP210101618A
Other languages
Spanish (es)
Inventor
Grant E Blouse
Brajesh Kumar
Tom Knudsen
Jan Kristian Jensen
Emil Oldenburg
Christine Ren Schar
Matthew John Traylor
Eric Steven Furfine
Jeffrey Charles Way
Agnieszka Jendroszek
Arzu Sandikci
Jim Mguire
Shyam Rajan Iyer
Moan Natacha Le
Original Assignee
Catalyst Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catalyst Biosciences Inc filed Critical Catalyst Biosciences Inc
Publication of AR122619A1 publication Critical patent/AR122619A1/en

Links

Landscapes

  • Peptides Or Proteins (AREA)

Abstract

En el presente documento se proporcionan variantes del factor I del complemento (CFI) que presentan al menos una característica mejorada en relación con un CFI de tipo natural. Las variantes de CFI de la divulgación pueden exhibir una especificidad y una actividad sintonizables. También se incluyen constructos de fusión que contienen CFI y que comprenden al menos un dominio de CFI, por ejemplo, CFI de tipo natural de longitud completa fusionado con albúmina sérica humana. También se incluyen métodos de fabricación y uso de dichas variantes de CFI y constructos de fusión. Las variantes de CFI y los constructos de fusión proporcionados en el presente documento pueden ser útiles para el tratamiento de una enfermedad o afección asociada con la desregulación del sistema del complemento o una deficiencia de CFI.Provided herein are complement factor I (CFI) variants that exhibit at least one improved characteristic relative to a wild-type CFI. The CFI variants of the disclosure may exhibit tunable specificity and activity. Also included are CFI-containing fusion constructs comprising at least one CFI domain, eg, full-length wild-type CFI fused to human serum albumin. Also included are methods of making and using such CFI variants and fusion constructs. The CFI variants and fusion constructs provided herein may be useful for the treatment of a disease or condition associated with dysregulation of the complement system or a CFI deficiency.

ARP210101618A 2020-06-14 2021-06-14 COMPOSITIONS AND METHODS RELATED TO COMPLEMENT FACTOR I AR122619A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063038874P 2020-06-14 2020-06-14

Publications (1)

Publication Number Publication Date
AR122619A1 true AR122619A1 (en) 2022-09-21

Family

ID=83444612

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101618A AR122619A1 (en) 2020-06-14 2021-06-14 COMPOSITIONS AND METHODS RELATED TO COMPLEMENT FACTOR I

Country Status (1)

Country Link
AR (1) AR122619A1 (en)

Similar Documents

Publication Publication Date Title
CL2022000036A1 (en) Modified polypeptides and uses thereof (divisional application no. 201900261)
EA201892561A1 (en) HYBRID PROTEINS GDF15 AND THEIR APPLICATION
CL2020000810A1 (en) Fusion proteins comprising enzyme replacement therapy enzymes.
CL2008002182A1 (en) Absorbent article with topsheet having first and second structurally modified zones comprising a first and second plurality of different holes; where the second zone is greater than 5% of the area of the upper canvas, not symmetrical with respect to, and its major axis is not parallel to, the longitudinal axis.
ECSP099688A (en) MOLECULES AND METHODS TO MODULATE PRO-PROTEIN
AR111288A1 (en) ANTI-PHF-TAU ANTIBODIES AND ITS USES
CR8978A (en) UNION DOMAIN FUSION PROTEINS
CL2019003813A1 (en) Modified membrane-type serine protease 1 polypeptides (mtsp-1) and methods of use.
CO6260094A2 (en) NEW ANTI-ALPHA5BETA1 ANTIBODIES AND USES OF THE SAME
CO6470858A2 (en) IMPROVED RECONSTITUTED TENSIOACTIVE COMPOSITION CONTAINING ANALOGS OF THE TENSIOACTIVE PROTEIN B (SP-B) AND THE TENSIOACTIVE PROTEIN C (SP-C)
ES2723050T3 (en) Thermostable phytase variants
BR112015021866A2 (en) GLA DOMAINS AS DRIVING AGENTS
WO2021257480A3 (en) Complement factor i-related compositions and methods
CL2021000650A1 (en) Modulators of pnpla3 expression
AR095555A1 (en) THERAPEUTIC USE OF ANTIBODIES DIRECTED TO THE HEPATOCITE GROWTH FACTOR (HGF)
UY30042A1 (en) NEW DERIVATIVES OF ALQUILFOSFOLÍPIDOS WITH REDUCED CYTOTOXICITY AND USES OF THE SAME.
EA201501028A1 (en) CONSTRUCTIONS OF MITOCHONDRIAL PROTEINS AND THEIR APPLICATION
ECSP20082339A (en) MODULATORS OF APOL1 EXPRESSION
CO2020013221A2 (en) Conjugates of the glucagon-like peptide-1 (glp-1) fusion peptide coupled to cyclic tyrosine tyrosine peptide and uses of these
CL2021003328A1 (en) Compositions comprising secretory iga and probiotics.
CO2023000307A2 (en) mybpc3 polypeptides and uses thereof
ECSP22078815A (en) ANTI-PHF-TAU ANTIBODIES AND THEIR USES
DOP2018000218A (en) CONJUGATED ESTERASE C1 INHIBITOR AND ITS USES
AR122619A1 (en) COMPOSITIONS AND METHODS RELATED TO COMPLEMENT FACTOR I
AR118853A1 (en) PHARMACEUTICAL FORMULATIONS CONTAINING CD80 EXTRACELLULAR DOMAIN FC FUSION PROTEINS